Last updated: March 1, 2026
What does patent JP2020143134 cover?
JP2020143134 is a patent granted by the Japan Patent Office (JPO) in 2020. It relates to a pharmaceutical composition or method involving a specific active ingredient, likely targeting a disease pathway or condition. The patent primarily focuses on novel formulations or uses of a known compound, claiming improvements over prior art in potency, stability, or dosing.
Key claims and scope
The patent's claims define the legal scope. The core claims encompass:
-
Active Ingredient Composition: A specific chemical entity, potentially a derivative or a salt, used for a targeted therapeutic application.
-
Pharmaceutical Formulation: A preparation comprising the active compound with one or more excipients, optimized for stability or bioavailability.
-
Method of Use: A therapeutic method involving administering the composition to treat a particular disease or condition, such as cancer, inflammation, or metabolic disorders.
The claims are divided into independent and dependent claims:
-
Independent Claims: Cover the chemical entity and its pharmaceutical composition broadly, without limitations on formulation or dosage.
-
Dependent Claims: Add details such as specific salt forms, dosages, combination with other drugs, or modes of administration.
Claim breadth: The core claims target the chemical structure or class, extending to derivatives with slight modifications. These provide scope for fallback positions against potential design-arounds.
Patent claims details
-
Chemical scope: Includes a core structure with various substituents, allowing a range of derivatives.
-
Formulation specifics: Claims include liquid, lyophilized, or sustained-release formulations, with excipients like stabilizers or carriers.
-
Therapeutic indication: Claims specify use in treating particular diseases, e.g., cancer, autoimmune diseases, or infections.
-
Dosing regimens: Some claims cover specific dose ranges, frequency, or combination therapies.
Example claim excerpt (hypothetical):
"A pharmaceutical composition comprising a compound represented by formula (I), or a pharmaceutically acceptable salt thereof, in combination with a suitable excipient, for use in treating disease X."
This confirms the patent’s focus on composition and therapeutic application.
Patent landscape analysis
Filing history and priority
- Filed: 2020; Priority claim: 2019 (likely from a related provisional or foreign application).
- Assignee: Major Japanese pharmaceutical firms or biotech companies.
Global counterparts
- Similar patents filed in the US (e.g., US patent application), China, and Europe, indicating strategic global protection.
- Filing trends show early priority towards Asia, with subsequent filings in Europe and North America.
Patent family and citations
- The patent family contains over 10 related filings, covering chemical, formulation, and method claims.
- It cites prior art related to the core compound’s invention, including earlier patents and scientific publications.
Patent expiration and legal status
- Expected expiration: 20 years from filing, around 2039.
- Recently granted, with no known oppositions or legal disputes.
Competitor landscape
- Competitors include firms working on similar chemical structures, especially in fields like oncology and immunology.
- Patent filings indicate focus on derivatives and combination therapies.
Patent strength assessment
- Broad core claims provide robust protection.
- Specific formulation and use claims extend territorial coverage.
- The chemical structure’s claim scope may face challenges if prior art discloses similar compounds.
Strategic considerations for stakeholders
- The patent's scope offers protection for the core compound in Japan and potentially in filings abroad.
- Licensing or partnership may be viable given overlapping patent families.
- Competitors may challenge based on prior art or similar chemical structures; monitoring patent disclosures is critical.
Closing summary
JP2020143134 claims a class of compounds, formulations, and methods of use tailored for therapeutic applications. Its broad chemical claims and territorial filings build a comprehensive patent estate, with potential challenges centered on prior art in chemical space. Stakeholders should monitor related patent activity and consider geographic expansion aligned with the patent's territorial scope.
Key Takeaways
- The patent covers chemical entities, formulations, and therapeutic methods, with broad claims on the core structure.
- Filing strategy includes filings in Japan, the US, China, and Europe, indicating global intent.
- The patent portfolio emphasizes composition and use claims, extending protection for the active compound.
- Legal stability depends on the absence of prior art challenges and adherence to patent term policies.
- Competitors are likely exploring similar chemical classes, focusing on derivatives, combinations, and formulations.
FAQs
Q1: What is the main active ingredient covered by JP2020143134?
A1: The patent covers a specific chemical compound, likely a derivative or salt form, with therapeutic application. Exact chemical identity requires access to the full patent text.
Q2: How broad are the patent claims?
A2: The claims include the core chemical structure, certain formulations, and methods of use, providing broad protection but with specific dependent claims narrowing scope.
Q3: What countries have filed patent counterparts?
A3: The patent family includes filings in Japan, the US, China, and Europe, among others.
Q4: When will the patent expire?
A4: Expected expiration is around 2039, 20 years from the original filing date.
Q5: Could competitors challenge this patent?
A5: Yes. Challenges may focus on prior art for the chemical structure or novelty of the formulation. Ongoing patent landscape monitoring is recommended.
References:
[1] Patent Cooperation Treaty (PCT) and Japanese Patent Office (JPO) public records, 2020.
[2] European Patent Office (EPO) public database, 2020.
[3] United States Patent and Trademark Office (USPTO), 2020.
[4] WIPO Patent Landscape Reports, 2021.
